Drugs Made In America Acquisition II Corp. Ordinary Shares (DMII) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Drugs Made In America Acquisition II Corp. Ordinary Shares (DMII) has a cash flow conversion efficiency ratio of -0.001x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-314.86K) by net assets ($487.16 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Drugs Made In America Acquisition II Corp. Ordinary Shares - Cash Flow Conversion Efficiency Trend (2024–2025)
This chart illustrates how Drugs Made In America Acquisition II Corp. Ordinary Shares's cash flow conversion efficiency has evolved over time, based on yearly financial data. See Drugs Made In America Acquisition II Cor (DMII) shareholders funds for net asset value and shareholders' equity analysis.
Drugs Made In America Acquisition II Corp. Ordinary Shares Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Drugs Made In America Acquisition II Corp. Ordinary Shares ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Newcapec Electronics Co Ltd
SHE:300248
|
0.022x |
|
CyberPower Systems Inc
TW:3617
|
0.053x |
|
Shenzhen Expressway Company Limited
F:SHZH
|
0.027x |
|
Sinostar Cable Co. Ltd.
SHE:300933
|
0.000x |
|
Nuveen Churchill Direct Lending Corp.
NYSE:NCDL
|
0.008x |
|
Third Coast Bancshares, Inc.
NYSE:TCBX
|
-0.059x |
|
Caisse Regionale de Credit Agricole Mutuel de Normandie Seine SC
PA:CCN
|
0.003x |
|
Jinneng Science&Tech Co Ltd
SHG:603113
|
-0.049x |
Annual Cash Flow Conversion Efficiency for Drugs Made In America Acquisition II Corp. Ordinary Shares (2024–2025)
The table below shows the annual cash flow conversion efficiency of Drugs Made In America Acquisition II Corp. Ordinary Shares from 2024 to 2025. For the full company profile with market capitalisation and key ratios, see Drugs Made In America Acquisition II Cor market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $487.16 Million | $-1.02 Million | -0.002x | -100.13% |
| 2024-12-31 | $-116.72K | $-194.30K | 1.665x | -- |
About Drugs Made In America Acquisition II Corp. Ordinary Shares
Drugs Made In America Acquisition II Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or other similar business combination with one or more businesses. The company was incorporated in 2024 and is based in Fort Lauderdale, Florida.